Grant writing is often the first step to a career beyond the traditional tenure track for many postdocs and graduate students. Grant writers secure funding for nonprofits (eg, NC Biotech Center, National Humanities Center), businesses (eg, local start-ups and mid-sized biotech firms), and government agencies. Increasingly, research universities employ grant officers to help faculty and staff secure funding. Consequently, skilled grant writers are typically able to find employment in an otherwise tough job market. As a bonus, grant writers often set their own hours and can work remotely.
In this session, two PhD grant writers and the CEO of an emerging life science company will describe this career, its possibilities for advancement, and local job opportunities in grant writing.
Dr. Eva Garland provides expertise in securing resources and leading teams to develop innovative technologies that span the biological and physical sciences. As Vice President of Research & Development for Agile Sciences in Raleigh NC, Dr. Garland was awarded over $6M in grant funds and led development of a new class of antibiotics for treating drug-resistant bacterial infections. Dr. Garland is the founder of Eva Garland Consulting, LLC (EGC). EGC assists small businesses in obtaining the resources they need to accelerate development of innovative technologies. The company specializes in developing strategies to secure grant funding; preparing high-quality grant applications; and effectively managing grant awards. Dr. Garland has recently published a book entitled “Winning SBIR/STTR Grants: A Ten Week Plan for Preparing Your NIH Phase I Application“, which is available on Amazon.com. She also serves as a regular member on a NIH Study Section that reviews SBIR/STTR grant applications from small businesses. Dr. Garland holds a BA in Chemistry from Columbia University and a PhD in Chemistry from Caltech, and was formerly a faculty member in the Chemistry department at NC State University.
Sam Tetlow is the CEO of EpiCypher, Inc. EpiCypher is pioneering the science of epigenetics, the study of health and disease caused by factors other than DNA. Mr. Tetlow has successful experience as an investor and entrepreneur in such companies as ILS Genomics, Immunologix, Gentris Corporation, and Tranzyme Pharma, among others, and has generated 5.1x return on invested capital as a result of last 13 years of investing track record. Mr. Tetlow holds an MBA from UNC Kenan-Flagler Business School (Beta Gamma Sigma) in 2003 and a BS in Aerospace Engineering from Worcester Polytechnic Institute (Honors) in 1993. Mr. Tetlow is an aspiring golfer, a former triathlete, and a strong proponent of community service
Nick Trotta completed his graduate and post-doctoral training at Vanderbilt University and Duke University, respectively. A neurobiologist by training, Dr Trotta is an independent consultant, working with small and start-up phase biotechnology companies to build grant funding pipelines, gather market knowledge and advance strategic partnerships. As Associate Director of Market Development for Advanced Liquid Logic, Inc, recently acquired by San Diego-based next generation sequencing leader Illumina, Inc., he identified new product opportunities in life science and applied markets, developed market research and commercialization strategies including distribution pathways, competition and pricing. Previously, Dr. Trotta led Affinergy’s small business grant writing efforts, culminating in over $10M in research support from various agencies within the National Institutes of Health.
LocationRm 143 Jones Bldg
- Professional Development